Condition (MeSH)
Fibrocystic Breast Disease
ClinicalTrials.gov lists 11 trials for Fibrocystic Breast Disease or a narrower condition beneath it. FemmePharma Global Healthcare, Inc. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
11 of the 11 trials are tagged with Fibrocystic Breast Disease itself; the rest are tagged with a narrower condition beneath it.
When did Fibrocystic Breast Disease trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2020 | 2 |
| 2016 | 1 |
| 2010 | 1 |
| 2009 | 2 |
| 2008 | 1 |
| 2007 | 1 |
| 2006 | 1 |
| 2005 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 11 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Fibrocystic Breast Disease trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 2 |
| Phase 4 | 3 |
| Observational | 2 |
How many Fibrocystic Breast Disease trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 6 |
| Terminated | 1 |
| Withdrawn | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Fibrocystic Breast Disease trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| FemmePharma Global Healthcare, Inc. | 2 |
| Catalysis SL | 1 |
| Symbollon Pharmaceuticals | 1 |
Which drugs are being tested for Fibrocystic Breast Disease? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Danazol | 2 |
| Evening Primrose Oil | 1 |
| Vitex Agnus Castus Extract | 1 |
| Abemaciclib | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Xiao Yao pills | 1 |
| IoGen (molecular iodine) | 1 |
| Xiaoru Sanjie capsules | 1 |
| Tamoxifen Pill | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Fibrocystic Breast Disease? (21)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial. | EBioMedicine | 2015 | Yes |
| Cystic breast masses and the ACRIN 6666 experience. | Radiologic clinics of North America | 2010 | Yes |
| Psychological impact of benign breast biopsy: a longitudinal, comparative study. | Health psychology : official journal of the Division of Health Psychology, American Psychological Association | 2002 | Yes |
| Significance of resistive index in color Doppler ultrasonogram: differentiation between benign and malignant breast masses. | Clinical imaging | 1999 | Yes |
| Tamoxifen-induced regression of breast cysts. | Clinical imaging | 1998 | Yes |
Showing 5 of 21 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.